Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences
September 19 2018 - 6:30AM
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted invitations
to participate in two upcoming investor conferences.
- At the Oppenheimer Fall Summit Focused on Specialty Pharma and
Rare Disease (September 26-27 in New York), senior management will
conduct a series of scheduled meetings with investment
professionals.
- At the Roth Capital Partners Battle of the NASH Thrones
Investor Conference (October 17 in New York), senior management
will conduct a series of scheduled meetings with investment
professionals and participate in a panel discussion on fibrotic,
inflammatory and metabolic agents.
About Conatus PharmaceuticalsConatus is a
biotechnology company focused on the development of novel medicines
to treat liver disease. In collaboration with Novartis, Conatus is
developing its lead compound, emricasan, for the treatment of
patients with chronic liver disease. Emricasan is a first-in-class,
orally active pan-caspase inhibitor designed to reduce the activity
of enzymes that mediate inflammation and apoptosis. Conatus
believes that by reducing the activity of these enzymes, caspase
inhibitors have the potential to interrupt the progression of a
variety of diseases. For additional information, please visit
www.conatuspharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts contained in
this press release are forward looking statements, including
statements regarding: caspase inhibitors' potential to
interrupt the progression of a variety of diseases. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplates,” “believes,”
“estimates,” “predicts,” “potential” or “continue” or the negative
of these terms or other similar expressions. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of risks, uncertainties and
assumptions, including those risks described in the company’s prior
press releases and in the periodic reports it files with the
Securities and Exchange Commission. The events and
circumstances reflected in the company’s forward-looking statements
may not be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements.
Except as required by applicable law, the company does not plan to
publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
CONTACT: Alan EngbringConatus
Pharmaceuticals Inc.(858) 376-2637aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Apr 2024 to May 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Conatus Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles